LY3053102 + exenatide extended-release

LY3053102 (also known as tirzepatide) + exenatide extended-release is a **combination of two injectable peptide drugs under investigation for the treatment of type 2 diabetes mellitus and potentially obesity**. - **LY3053102/tirzepatide** is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor, sometimes described as a "twincretin." It stimulates insulin secretion and reduces glucagon secretion in a glucose-dependent manner, and can also slow gastric emptying and induce weight loss. - **Exenatide extended-release** is a GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon secretion, slows gastric emptying, and promotes weight loss[1][3]. The combination is designed to leverage the complementary incretin actions for improved glycemic control and weight reduction.

Brand names

none identified for the combination

Other names

tirzepatide + exenatide extended-release